GlaxoSmithKline plc (ADR)  

(Public, NYSE:GSK)   Watch this stock  
Find more results for gsk
45.01
+0.05 (0.11%)
Jan 23 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 44.77 - 45.25
52 week 41.25 - 56.73
Open 44.87
Vol / Avg. 3.10M/4.54M
Mkt cap 109.49B
P/E 17.50
Div/yield 0.61/5.89
EPS 2.57
Shares 4.85B
Beta 0.66
Inst. own 5%
Feb 4, 2015
Q4 2014 GlaxoSmithKline PLC Earnings Release - 3:00AM EST - Add to calendar
Jan 13, 2015
GlaxoSmithKline PLC at JPMorgan Healthcare Conference (Q&A)
Jan 13, 2015
GlaxoSmithKline PLC at JPMorgan Healthcare Conference
Dec 18, 2014
GlaxoSmithKline PLC Ordinary Shareholders Meeting
Dec 3, 2014
GlaxoSmithKline PLC at Berenberg European Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 6.82% 21.23%
Operating margin 12.45% 27.58%
EBITD margin - 34.46%
Return on average assets 3.90% 13.47%
Return on average equity 28.82% 84.96%
Employees 99,817 -
CDP Score - 98 A

Address

980 Great West Road
BRENTFORD, TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 49
Bio & Compensation  - Reuters
Simon Dingemans Chief Financial Officer, Executive Director
Age: 50
Bio & Compensation  - Reuters
Moncef Slaoui Chairman, Executive Director
Age: 54
Bio & Compensation  - Reuters
Deirdre P. Connelly President - North American Pharmaceuticals
Age: 53
Bio & Compensation  - Reuters
Roger Connor President - Global Manufacturing & Supply
Bio & Compensation  - Reuters
Shah Abbas Hussain President - Europe, Japan & EMAP
Age: 49
Bio & Compensation  - Reuters
Patrick Vallance President - Pharmaceuticals R&D
Bio & Compensation  - Reuters
Emma Walmsley President - Consumer Healthcare Worldwide
Bio & Compensation  - Reuters
Daniel Troy Senior Vice President, General Counsel
Bio & Compensation  - Reuters
Claire Thomas Senior Vice President - Human Resources
Bio & Compensation  - Reuters